



Biotech Daily

Friday May 14, 2010

Daily news on ASX-listed biotechnology companies

*** ASX DOWN, BIOTECH FLAT: VIRALYTICS UP 11%; GENERA DOWN 8%**

*** CBIO DOSES 1st EURO PATIENT IN PHASE IIa XTOLL ARTHRITIS TRIAL**

*** SUN SHARE PLAN RAISES \$856k TO REVIVE OCCUPATIONAL & MEDICAL**

MARKET REPORT

The Australian stock market fell 0.9 percent on Friday May 14, 2010 with the S&P ASX 200 down 41.7 points to 4611.1 points. It was a quiet day for biotech.

Fourteen of the Biotech Daily Top 40 stocks were up, 13 fell, six traded unchanged and seven were untraded.

Viralytics was best, up half a cent or 10.6 percent to 5.2 cents with 29.7 million shares traded, followed by Clinuvel up seven percent to 23 cents with 114,321 shares traded.

Cellmid, Mesoblast and Patrys climbed more than four percent; Alchemia, Impedimed and Sunshine Heart were up more than three percent; Novogen and QRX rose more than two percent; with Chemgenex and Living Cell up more than one percent.

Genera led the falls, down five cents or 7.7 percent to 60 cents with 5,000 shares traded.

Biota and Phosphagenics lost more than six percent; Antisense and Tissue Therapies were down five percent or more; Bionomics, Compumedics and Prima were down more than three percent; Benitec shed 2.6 percent; with Universal Biosensors down 1.3 percent.

[CBIO](#)

CBio says it has dosed the first European patient in its phase IIa clinical trial in rheumatoid arthritis.

CBio said the 150-patient trial of its lead drug candidate XToll was being conducted at trial sites in Australia, New Zealand and Europe.

The company said the European sites had more than 25 patients for the trial in pre-screening or screening stages.

CBio said it expected to complete recruitment of 150 patients by the end of September 2010.

CBio was unchanged at 39 cents.

[SUN BIOMEDICAL, OCCUPATIONAL & MEDICAL INNOVATIONS](#)

Sun Biomedical has raised \$856,865, partly to refloat the suspended Occupational & Medical which is in voluntary administration.

Sun said yesterday that it had completed its share purchase plan but provided no details.

Today the ASX's head of communications told Biotech Daily that the raising was "fully unwritten - so the full amount, as initially disclosed, has been raised".

Sun said on March 10, 2010 the share plan at 0.16 cents a share would be capped at \$855,865 and the funds raised would be used for working capital to identify, assess and pursue potential investment opportunities.

On April 1, 2010 Sun said the share plan was fully underwritten by Patersons Securities.

On May 6, 2010 Sun said it would invest in Occupational & Medical Innovations, which has been suspended since October 1, 2009 and in voluntary administration since December 31, 2009 (BD: Jan 17, 25, 2010).

Sun was unchanged at 0.1 cents.

Occupational & Medical last traded at 14.5 cents.